Acquisitions, Investments, and Licenses - Textual (Details)
|
3 Months Ended | 6 Months Ended | 1 Months Ended | 0 Months Ended | 0 Months Ended | 1 Months Ended | 12 Months Ended | 1 Months Ended | 6 Months Ended | 1 Months Ended | 1 Months Ended | 0 Months Ended | 0 Months Ended | 1 Months Ended | 0 Months Ended | 1 Months Ended | |||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Jun. 30, 2014
USD ($)
|
Jun. 30, 2013
USD ($)
|
Jun. 30, 2014
USD ($)
|
Jun. 30, 2013
USD ($)
|
Dec. 31, 2013
USD ($)
|
Jun. 30, 2012
SciVac
Variable Interest Entity, Primary Beneficiary
USD ($)
member
|
Jun. 30, 2014
SciVac
Variable Interest Entity, Primary Beneficiary
USD ($)
|
May 16, 2014
Common stock investments, available for sale
Rate
|
Jan. 16, 2014
Biozone
Equity Method Investee
USD ($)
|
Jan. 03, 2014
Biozone
Equity Method Investee
|
Jan. 02, 2014
Biozone
Equity Method Investee
|
Jan. 16, 2014
Biozone
Equity Method Investee
|
Jan. 03, 2014
Biozone
Equity Method Investee
Series B Convertible Preferred Stock
|
Jan. 02, 2014
Biozone
Equity Method Investee
Series B Convertible Preferred Stock
|
Oct. 31, 2013
ARNO
USD ($)
|
Oct. 31, 2013
ARNO
Equity Method Investee
USD ($)
|
Dec. 31, 2013
Neovasc
USD ($)
|
Dec. 31, 2011
Neovasc
USD ($)
|
Jan. 31, 2014
Pharmsynthez
|
Apr. 30, 2013
Pharmsynthez
USD ($)
|
Apr. 30, 2013
Pharmsynthez
RUB
|
Jun. 30, 2014
Pharmsynthez
USD ($)
|
Mar. 31, 2013
RXi Pharmaceuticals Corporation
USD ($)
|
Oct. 31, 2013
Zebra
USD ($)
|
Oct. 31, 2013
Zebra
Series A Preferred Stock
|
Oct. 31, 2013
Zebra
Restricted Stock
|
May 16, 2014
Senesco
Common stock investments, available for sale
|
May 16, 2014
Senesco
Common stock investments, available for sale
|
May 16, 2014
Fabrus
Common stock investments, available for sale
|
Oct. 31, 2013
One Year Warrants
ARNO
Equity Method Investee
|
Oct. 31, 2013
Five Year Warrants
ARNO
Equity Method Investee
|
Apr. 17, 2014
Inspiro
USD ($)
|
Apr. 17, 2014
Inspiro
USD ($)
|
Aug. 31, 2013
OPKO Biologics
USD ($)
|
Mar. 31, 2013
OPKO Renal
USD ($)
|
|
Business Acquisition [Line Items] | |||||||||||||||||||||||||||||||||||
Inspiro stock purchase agreement | 100.00% | ||||||||||||||||||||||||||||||||||
Cash paid at closing date | $ 700,000 | $ 1,500,000 | |||||||||||||||||||||||||||||||||
Common stock value | 8,600,000 | 540,600,000 | 146,900,000 | ||||||||||||||||||||||||||||||||
Number of trading days | 10 days | 10 days | |||||||||||||||||||||||||||||||||
Stock price | $ 8.57 | $ 8.49 | $ 7.16 | ||||||||||||||||||||||||||||||||
In process research and development | 10,055,000 | 0 | 10,055,000 | 0 | 10,100,000 | ||||||||||||||||||||||||||||||
Shares conversion ratio | 0.9951 | ||||||||||||||||||||||||||||||||||
Delivery of common stock | 999,556 | 63,670,805 | 20,517,030 | ||||||||||||||||||||||||||||||||
Options and warrants outstanding (shares) | 7,889,265 | ||||||||||||||||||||||||||||||||||
Fair value of warrants outstanding | 3,600,000 | 46,100,000 | |||||||||||||||||||||||||||||||||
Percentage of ownership held by chairman | 5.00% | ||||||||||||||||||||||||||||||||||
Percentage of ownership held by directors | 5.00% | ||||||||||||||||||||||||||||||||||
Business acquisition share price on shares issue | $ 9.00 | $ 4.87 | |||||||||||||||||||||||||||||||||
Amount payable in cash or shares on achieving milestones for acquiring a product in development | 190,000,000 | ||||||||||||||||||||||||||||||||||
Contingent consideration | 72,900,000 | 72,900,000 | 71,600,000 | 47,700,000 | |||||||||||||||||||||||||||||||
Noncash or Part Noncash Acquisition, Noncash Financial or Equity Instrument Consideration, Shares Issued | 1,000,000 | 1,000,000 | |||||||||||||||||||||||||||||||||
Stock Conversion, Common Shares Issued upon Conversion | 205.08308640 | 205.08308640 | |||||||||||||||||||||||||||||||||
Invested in common shares | 500,000 | 2,000,000 | 1,200,000 | 2,000,000 | 2,500,000 | 2,000,000 | |||||||||||||||||||||||||||||
Warrants to purchase common shares | 1,000,000 | 1,000,000 | 833,333 | 833,333 | |||||||||||||||||||||||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights | 0.50 | 2.40 | 4.00 | ||||||||||||||||||||||||||||||||
Warrants expiration period | 2 years | 1 year | 5 years | ||||||||||||||||||||||||||||||||
Number of shares purchased | 2,000,000 | 13,600,000 | 13,600,000 | 17,241,380 | |||||||||||||||||||||||||||||||
Investment Warrants, Exercise Price | $ 1.25 | ||||||||||||||||||||||||||||||||||
Asset Purchase Agreement | 9,600,000 | ||||||||||||||||||||||||||||||||||
Number of share options received in purchase agreement | 12,000,000 | 12,000,000 | |||||||||||||||||||||||||||||||||
Proceeds to be received from sale of proprietary technology | 8,100,000 | 265,000,000 | |||||||||||||||||||||||||||||||||
Shares Received In Satisfaction of Notes Receivable | 12,000,000 | ||||||||||||||||||||||||||||||||||
Deferred revenue | 8,300,000 | 8,300,000 | 8,300,000 | 9,500,000 | |||||||||||||||||||||||||||||||
Period for development of technology | 3 years | 3 years | |||||||||||||||||||||||||||||||||
Deferred revenue received from collaboration agreement | 1,400,000 | ||||||||||||||||||||||||||||||||||
Revenue related to our license agreements | 500,000 | ||||||||||||||||||||||||||||||||||
Revenue collaboration agreement, offset to research and development | 800,000 | ||||||||||||||||||||||||||||||||||
Issue of common stock shares | 50,000,000 | ||||||||||||||||||||||||||||||||||
Milestone payments | 50,000,000 | ||||||||||||||||||||||||||||||||||
Asset purchase agreement financing for Rxi | 16,400,000 | ||||||||||||||||||||||||||||||||||
New Options Ratio | 0.376939 | ||||||||||||||||||||||||||||||||||
Conversion of Stock, Shares Converted | 80,000 | ||||||||||||||||||||||||||||||||||
Shares, Outstanding | 1,159,380 | ||||||||||||||||||||||||||||||||||
Equity Method Investment, Third Party Purchase of Investment, Conversion of Shares, Shares Issued in New Entity | 437,016 | ||||||||||||||||||||||||||||||||||
Investment Owned, Balance, Shares | 1,000,000 | 833,333 | 840,000 | 517,016 | |||||||||||||||||||||||||||||||
Number of Shares Warrants Acquired in Equity Method Investment | 267,927 | ||||||||||||||||||||||||||||||||||
Cocrystal on a fully diluted basis | 50.00% | ||||||||||||||||||||||||||||||||||
Additional working capital | 2,600,000 | ||||||||||||||||||||||||||||||||||
Number of members of board of directors | 5 | ||||||||||||||||||||||||||||||||||
Number of members of board of directors appointed by reporting entity | 3 | ||||||||||||||||||||||||||||||||||
Percent of board of directors appointed by reporting entity | 60.00% | ||||||||||||||||||||||||||||||||||
Shares Received As Gift | 900,000 | ||||||||||||||||||||||||||||||||||
Equity Method Investment, Ownership Percentage | 23.50% | ||||||||||||||||||||||||||||||||||
Total assets of equity method investees | 131,400,000 | 131,400,000 | |||||||||||||||||||||||||||||||||
Total liabilities of equity method investees | 17,700,000 | 17,700,000 | |||||||||||||||||||||||||||||||||
Net losses of equity method investees | $ 25,200,000 |